Home/Filings/4/0001209191-18-019375
4//SEC Filing

Sakoda Jon 4

Accession 0001209191-18-019375

CIK 0001412067other

Filed

Mar 12, 8:00 PM ET

Accepted

Mar 13, 6:08 PM ET

Size

6.1 KB

Accession

0001209191-18-019375

Insider Transaction Report

Form 4
Period: 2018-03-09
Sakoda Jon
10% Owner
Transactions
  • Disposition from Tender

    Common Stock

    2018-03-0910,882,5740 total(indirect: See Note 2)
Footnotes (2)
  • [F1]Shares of Common Stock tendered in the tender offer launched by Valley Acquisition Sub, Inc. on February 8, 2018 pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc., to acquire all of the outstanding shares of common stock of Cascadian Therapeutics, Inc., par value $0.001 per share, at a purchase price of $10.00 per share, net to the seller in cash, without interest and less any required withholding taxes.
  • [F2]The Reporting Person is a manager of NEA 15 GP, LLC, ("NEA 15 GP") which is the sole general partner of NEA Partners 15, L.P. ("NEA Partners 15"). NEA Partners 15 is the sole general partner of New Enterprise Associates 15, L. P. ("NEA 15"). NEA 15 is the sole member of Growth Equity Opportunities Fund IV, LLC ("GEO IV"), which is the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares held by GEO IV in which the Reporting Person has no pecuniary interest.

Issuer

Cascadian Therapeutics, Inc.

CIK 0001412067

Entity typeother

Related Parties

1
  • filerCIK 0001589961

Filing Metadata

Form type
4
Filed
Mar 12, 8:00 PM ET
Accepted
Mar 13, 6:08 PM ET
Size
6.1 KB